Sunho Biologics Inc. has announced the resignation of its auditor, Deloitte Touche Tohmatsu, effective immediately due to a disagreement over the audit fee for the financial year ending December 31, 2025. The board of directors and the audit committee evaluated Deloitte's proposal alongside those from other firms, considering factors like industry experience and proposed fees. As Deloitte had not begun any audit work for the current fiscal year, the company expects no significant impact on its annual audit. Sunho Biologics is in the process of appointing a new auditor and will announce the appointment in due course. The company expressed appreciation for Deloitte's services during its tenure.